GleamWall
中文EN

GCTK Glucotrack, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1506983 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY40.4%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-620.6%
ROA-272.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets216.5%
Debt / equity—
Current ratio0.46x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$9.81M$9.50M
SG&A expense$6.28M$5.05M
Operating income-$16.09M-$14.55M
Interest expense—$44,000
Net income-$19.39M-$22.60M
EBITDA-$16.05M-$14.51M
EPS (basic)31.224,106.00
EPS (diluted)31.224,106.00
Weighted avg. shares (diluted)621,0945,503
Balance sheet
Cash & equivalents$7.38M$5.62M
Current assets$7.67M$5.77M
PP&E, net$138,000$95,000
Total assets$7.84M$5.93M
Current liabilities$4.77M$1.27M
Total liabilities$5.01M$18.93M
Shareholders' equity$2.83M-$13.00M
Shares outstanding910,68813,409
Cash flow statement
Operating cash flow-$15.24M-$12.49M
Capital expenditure$96,000$104,000
Free cash flow-$15.34M-$12.59M
Investing cash flow-$96,000-$104,000
Financing cash flow$17.04M$13.74M
Depreciation & amortization$42,000$36,000
Stock-based compensation$211,000$173,000

Free plan shows the latest 2 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.